Psoriasis: regaining efficacy with secukinumab following loss of response

  • Augustin M & al.
  • Br J Dermatol
  • 10 Apr 2019

  • curated by Dawn O'Shea
  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Secukinumab (Cosentyx) is associated with stable efficacy at 52 weeks in a majority of patients with moderate-to-severe psoriasis in post hoc analyses of the FIXTURE and CLEAR trials.

Why this matters

  • This analysis adds further support for sustained efficacy of secukinumab.

Key results

  • In the CLEAR trial at 52 weeks, 90.2% of patients showed stable efficacy without loss of response and 77.7% showed stable efficacy without reduction of response (compared with 74.2% and 59.9%, respectively, of patients who received ustekinumab (Stelara).
  • In the FIXTURE trial at 52 weeks, 83.5% of patients showed stable efficacy without loss of response and 66.4% of patients showed stable efficacy without reduction of response (compared with 58.3% and 42.6%, respectively, of patients who received etanercept (Enbrel).
  • Of patients who experienced loss of response, 50.0% (CLEAR trial) and 26.5% (FIXTURE trial) regained response by continuing secukinumab.

Study design

  • CLEAR included 336 patients who received secukinumab and 339 who received ustekinumab.
  • FIXTURE included 327 patients who received secukinumab and 326 patients who received etanercept.
  • Response categories were defined based on Psoriasis Area and Severity Index reduction from baseline.
  • Funding: Novartis Pharma GmbH

Limitations

  • Post hoc analysis limits statistical analysis and comparisons between trials.